Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cerdulatinib - Dermavant Sciences/Alexion AstraZeneca Rare Disease

Next Previous
Drug Profile

Cerdulatinib - Dermavant Sciences/Alexion AstraZeneca Rare Disease

Alternative Names: ALXN 2075; DMVT 502; Dual-SYK/JAK-inhibitor-Alexion AstraZeneca Rare Disease; PRT-062070; PRT-2070; RVT-502; RVT-502 - Dermavant Sciences

Latest Information Update: 12 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Portola Pharmaceuticals
  • Developer Alexion AstraZeneca Rare Disease; Dermavant Sciences; NicOx; Portola Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antineoplastics; Antirheumatics; Cyclopropanes; Eye disorder therapies; Piperazines; Pyrimidines; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma; Non-Hodgkin's lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • No development reported Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Discontinued Allergic rhinitis; Atopic dermatitis; Eye disorders; Vitiligo

Most Recent Events

  • 28 Oct 2024 Dermavant Sciences has been acquired by Organon
  • 28 Jul 2024 No recent reports of development identified for preclinical development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma in Australia
  • 19 Mar 2024 Alexion Pharmaceuticals completes a expanded access programme in Chronic lymphocytic leukemia and Non-hodgkin's lymphoma in March 2024 (NCT04757259)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top